Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib + anlotinib in advanced EGFR atypical-mutant non-small cell lung cancer
ChiCTR2400084053Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunvozertinib and anlotinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Started May 2024; status: recruiting.
02
Drugs
sunvozertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400084053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084053.